Next generation oncolytic viruses expressing PADI1 and TIMP2 exhibit anti-tumor activity against melanoma in nude and humanized mouse models

Lukasz Kuryk; Anne-Sophie W Møller

doi:10.1016/j.omto.2023.01.002

Next generation oncolytic viruses expressing PADI1 and TIMP2 exhibit anti-tumor activity against melanoma in nude and humanized mouse models

Mol Ther Oncolytics. 2023 Jan 13:28:158-170. doi: 10.1016/j.omto.2023.01.002. eCollection 2023 Mar 16.

Authors

Lukasz Kuryk^{1

2}, Anne-Sophie W Møller¹

Affiliations

¹ Targovax ASA, Clinical Science, Vollsveien 19, NO-1366 Lysaker Oslo, Norway.
² National Institute of Public Health NIH - National Research Institute, Department of Virology, Chocimska 24, 00-791 Warsaw, Poland.

Abstract

Immunotherapy of metastatic melanoma (MM) has vastly improved the longevity of only a minority of patients. To broaden the repertoire of agents against MM, we investigated the effectiveness of locally interrupting tumor blood endothelial cell proliferation and angiogenesis, arginine deprivation, or both on the growth of melanoma by constructing and characterizing the effectiveness of four oncolytic adenoviruses. ONCOS-207 (which expressed tissue inhibitor of metalloprotease type 2 [TIMP2]), ONCOS-209 (which expressed peptidyl arginine deiminase [PADI1]), and ONCOS-210 and ONCOS-212 (which expressed both TIMP2 and PADI1) exhibited oncolytic activity against four melanoma cell lines in vitro. ONCOS-212 treatments significantly inhibited tumor growth in an A2058 tumor model in nude mice compared with vehicle control. The inhibitory effects of the two transgenes of ONCOS-212 on tumor growth appeared to be synergistic. These viruses also significantly inhibited tumor growth in a humanized NOG model of melanoma (A2058 xenograft). All viruses significantly increased the percentage of activated CD8+ T cells in the tumor-infiltrating lymphocytes. The abscopal effect of ONCOS-212 treatments in the A2058 tumor challenge model in hNOG mice supports the hypothesis that the human immune response contributes to the anti-tumor activity of ONCOS-212. These results support the further development of ONCOS-212 for cancer treatment.

Keywords: PADI1; TIMP2; animal studies; arginine deiminase; arginine deprivation; cancer models; humanized NOG tumor model; immunotherapy; melanoma; oncolytic adenovirus.